Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
February 14 2024 - 4:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G/A
(Amendment
No. 1)
Under
the Securities Exchange Act of 1934
Lantern
Pharma Inc.
(Name
of Issuer)
Common
Stock, $0.0001 par value per share
(Title
of Class of Securities)
51654W101
(CUSIP
Number)
December
31, 2023
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☒
Rule 13d-1(c)
☐
Rule 13d-1(d)
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes)
CUSIP
No. 51654W101
1. |
NAMES
OF REPORTING PERSONS
ProPhase
Labs, Inc.
|
|
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a)
☐ (b) ☐
|
|
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5. |
SOLE
VOTING POWER
631,195 |
6. |
SHARED
VOTING POWER
0 |
7. |
SOLE
DISPOSITIVE POWER
631,195 |
8. |
SHARED
DISPOSITIVE POWER
0 |
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
631,195
|
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8%
(1) |
12. |
TYPE
OF REPORTING PERSON (see instructions)
CO |
(1) |
Based
on 10,869,040 shares outstanding as of November 3, 2023 according to the quarterly report on Form 10-Q filed by the Issuer with the
Securities and Exchange Commission on November 8, 2023. |
Item
1.
(a) Name of Issuer:
Lantern
Pharma Inc. (the “Issuer”)
(b) Address of Issuer’s Principal Executive Offices:
1920
McKinney Avenue, 7th Floor Dallas, Texas 75201
Item
2.
(a)-(c)
Name, Address and Citizenship of Reporting Persons
ProPhase
Labs, Inc.
711
Stewart Ave, Suite 200
Garden
City, New York 11530
Place
of Incorporation: Delaware
(d) Title of Class of Securities
Common
Stock, $0.0001 par value per share (“Common Stock”)
(e) CUSIP Number
51654W101
Item
3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not
applicable.
Item
4. Ownership.
(a) Amount Beneficially Owned:
Please
refer to items 5-9 of the cover pages attached hereto.
(b) Percent of Class
Please
refer to item 11 of the cover pages attached hereto
(c) Number of shares as to which such person has:
Please
refer to items 5-8 of the cover pages attached hereto
Item
5. Ownership of Five Percent or Less of a Class.
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following: ☐
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
Not
applicable.
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not
applicable.
Item
8. Identification and Classification of Members of the Group.
Not
applicable.
Item
9. Notice of Dissolution of Group.
Not
applicable.
Item
10. Certification.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely
in connection with a nomination under § 240.14a-11.
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Date:
February 14, 2024 |
PROPHASE
LABS, INC. |
|
|
|
|
By: |
/s/
Ted Karkus |
|
Name: |
Ted
Karkus |
|
Title: |
Chairman
of the Board and Chief Executive Officer |
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Sep 2023 to Sep 2024